Une étude sur le talquetamab avec d'autres traitements anticancéreux chez des participants atteints de myélome multiple (MonumenTAL-2)
Une étude de phase 1b à plusieurs bras sur le talquetamab avec d'autres traitements anticancéreux chez des participants atteints de myélome multiple
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Fitzroy, Australie, 3065
- St Vincents Hospital Melbourne
-
Melbourne, Australie, 3004
- Alfred Health
-
Southport, Australie, 4215
- Gold Coast University Hospital
-
Wollongong, Australie, 2500
- Wollongong Hospital
-
-
-
-
-
Brussels, Belgique, 1200
- Cliniques Universitaires St-Luc
-
Edegem, Belgique, 2650
- UZA
-
Ghent, Belgique, 9000
- UZ Gent
-
Leuven, Belgique, 3000
- UZ Leuven
-
-
-
-
-
Nantes, France, 44093
- CHU Nantes
-
Pessac, France, 33604
- CHU de Bordeaux - Hospital Haut-Leveque
-
Rennes, France, 35000
- Chu Rennes Hopital Pontchaillou
-
Toulouse, France, 31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
Groningen, Pays-Bas, 9713 GZ
- UMCG
-
Maastricht, Pays-Bas, 6229 HX
- Maastricht University Medical Centre
-
Utrecht, Pays-Bas, 3584 CX
- UMCU
-
-
-
-
-
London, Royaume-Uni, W1T 7HA
- University College Hospital London
-
Manchester, Royaume-Uni, M20 4BX
- The Christie Nhs Foundation Trust
-
Oxford, Royaume-Uni, OX3 7LE
- Churchill Hospital
-
Surrey, Royaume-Uni, SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama Birmingham
-
-
California
-
San Francisco, California, États-Unis, 94143
- University of California San Francisco
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Colorado Blood Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, États-Unis, 10065
- Weill Cornell Medical College
-
New York, New York, États-Unis, 10029
- Mt. Sinai School of Medicine
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Levine Cancer Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Tennessee Oncology
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College Of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
- Have measurable disease at screening as defined by at least 1 of the following: a. Serum monoclonal protein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL); or b. Urine M-protein level >= 200 milligrams (mg)/24 hours; or c. Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at screening and immediately before the start of study treatment administration
- A woman of childbearing potential must have a negative highly sensitive serum beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine or serum pregnancy test within 24 hours before the start of study treatment administration
- Be willing and able to adhere to the lifestyle restrictions specified in the protocol, including adherence to the applicable immunomodulatory drug (IMiD) global Pregnancy Prevention Plan (PPP) or local PPP/Risk Evaluation and Mitigation Strategy (REMS) program
Exclusion Criteria:
- Live, attenuated vaccine within 4 weeks before the first dose of study treatment
- Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within the 14-day period before the start of study treatment administration
- Active central nervous system (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Known to be seropositive for human immunodeficiency virus
- History of stroke or seizure within 6 months prior to the first dose of study treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment Regimen A: Talquetamab + Carfilzomib
Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion. |
Talquetamab will be administered subcutaneously.
Autres noms:
Carfilzomib will be administered as an IV infusion. |
|
Expérimental: Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib
Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion. |
Talquetamab will be administered subcutaneously.
Autres noms:
Carfilzomib will be administered as an IV infusion. Daratumumab will be administered subcutaneously. |
|
Expérimental: Treatment Regimen C: Talquetamab + Lenalidomide
Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally. |
Talquetamab will be administered subcutaneously.
Autres noms:
Lenalidomide will be self-administered orally. |
|
Expérimental: Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide
Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally. |
Talquetamab will be administered subcutaneously.
Autres noms:
Daratumumab will be administered subcutaneously. Lenalidomide will be self-administered orally. |
|
Expérimental: Treatment Regimen E: Talquetamab + Pomalidomide
Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally. |
Talquetamab will be administered subcutaneously.
Autres noms:
Pomalidomide will be self-administered orally. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Délai: Up to 1 year and 10 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 1 year and 10 months
|
|
Number of Participants with AEs by Severity
Délai: Up to 1 year and 10 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to AE. |
Up to 1 year and 10 months
|
|
Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters
Délai: Up to 1 year and 6 months
|
Number of participants with clinically significant abnormalities in laboratory parameters such as hematology and serum chemistry will be reported. |
Up to 1 year and 6 months
|
|
Number of Participants with Dose Limiting Toxicity (DLT)
Délai: Up to 49 days
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity of grade 3 or higher, clinical laboratory abnormalities, or hematologic toxicity. |
Up to 49 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Response Rate (ORR)
Délai: Up to 1 year and 10 months
|
ORR is defined as the percentage of participants who achieve partial response (PR) or better according to the International Myeloma Working Group (IMWG) 2016 criteria. Response to treatment will be evaluated by the investigator based on IMWG criteria. |
Up to 1 year and 10 months
|
|
Very Good Partial Response (VGPR) or Better Response Rate
Délai: Up to 1 year and 10 months
|
VGPR or better response rate is defined as the percentage of participants who achieve a VGPR or better response (stringent complete response [sCR] + complete response [CR] +VGPR) according to the IMWG 2016 criteria. |
Up to 1 year and 10 months
|
|
Complete Response (CR) or Better Response Rate
Délai: Up to 1 year and 10 months
|
CR or better response rate is defined as the percentage of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 1 year and 10 months
|
|
Stringent Complete Response (sCR)
Délai: Up to 1 year and 10 months
|
sCR rate is defined as the percentage of participants who achieve an sCR according to the IMWG 2016 criteria. |
Up to 1 year and 10 months
|
|
Duration of Response
Délai: Up to 1 year and 10 months
|
Duration of response is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG 2016 criteria, or death due to disease progression, whichever occurs first. |
Up to 1 year and 10 months
|
|
Time to Response
Délai: Up to 1 year and 10 months
|
Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better. |
Up to 1 year and 10 months
|
|
Serum Concentration of Talquetamab
Délai: Up to 1 year and 10 months
|
Serum samples will be analyzed to determine concentrations of talquetamab. |
Up to 1 year and 10 months
|
|
Serum Concentration of Daratumumab
Délai: Up to 1 year and 10 months
|
Serum samples will be analyzed to determine concentrations of daratumumab for treatment regimens B and D. |
Up to 1 year and 10 months
|
|
Number of Participants with Anti-Drug Antibodies to Talquetamab
Délai: Up to 1 year and 10 months
|
Number of participants with anti-drug antibodies to talquetamab will be reported. |
Up to 1 year and 10 months
|
|
Number of Participants with Anti-Drug Antibodies to Daratumumab
Délai: Up to 1 year and 10 months
|
Number of participants with anti-drug antibodies to daratumumab will be reported for treatment regimens B and D. |
Up to 1 year and 10 months
|
|
Number of Participants with Anti-Drug Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)
Délai: Up to 1 year and 10 months
|
Number of participants with anti-drug antibodies to rHuPH20 will be reported. |
Up to 1 year and 10 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Tumeurs, plasmocyte
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Troubles hémorragiques
- Maladies hémiques et lymphatiques
- Myélome multiple
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Acides carboxyliques
- Pipéridines
- Phtalimides
- Acides phtaliques
- Acides, carbocyclique
- Pipéridones
- Isoindoles
- Lénalidomide
- carfilzomib
- pomalidomide
- talquetamab
Autres numéros d'identification d'étude
- CR108946
- 2020-004502-55 (Numéro EudraCT)
- 64407564MMY1004 (Autre identifiant: Janssen Research & Development, LLC)
- 2023-503620-60-00 (Identificateur de registre: EUCT number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .